Compare HFFG & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HFFG | PBYI |
|---|---|---|
| Founded | 1997 | 2010 |
| Country | United States | United States |
| Employees | 960 | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.8M | 467.2M |
| IPO Year | 2016 | 2011 |
| Metric | HFFG | PBYI |
|---|---|---|
| Price | $1.67 | $9.14 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 82.7K | ★ 267.6K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.65 | N/A |
| EPS | 0.07 | ★ 0.08 |
| Revenue | ★ $1,228,282,000.00 | $27,685,000.00 |
| Revenue This Year | $5.59 | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | ★ $23.71 | $114.00 |
| Revenue Growth | ★ 2.21 | N/A |
| 52 Week Low | $1.38 | $4.30 |
| 52 Week High | $3.59 | $9.74 |
| Indicator | HFFG | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 38.27 | 52.71 |
| Support Level | $1.40 | $8.78 |
| Resistance Level | $1.97 | $9.55 |
| Average True Range (ATR) | 0.07 | 0.35 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 6.36 | 38.74 |
HF Foods Group Inc is an Asian food service distributor that markets and distributes fresh produce, frozen and dry food, and non-food products to Asian restaurants and other foodservice customers throughout the United States. The company's business consists of one operating segment: HF Group, which operates solely in the United States. The company's product list consists of Meat, Poultry & Seafood, Sauces & Oils, Takeout Items (Boxes, Chopsticks & Utensils), Raw Ingredients (Flour, Cornstarch, Spices), Cleaning Supplies, and Rice & Grains.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.